Brief: Rafael Holdings Provides Update On Rafael Pharmaceuticals’ Two Phase 3 Trials Of Cpi-613

Rafael Holdings

28/10/2021 13:35

Oct 28 (Reuters) - Rafael Holdings Inc  RFL.N :
    * RAFAEL HOLDINGS PROVIDES UPDATE ON RAFAEL PHARMACEUTICALS’
TWO
PHASE 3 TRIALS OF CPI-613® (DEVIMISTAT), AVENGER 500 IN
METASTATIC PANCREATIC CANCER AND ARMADA 2000 IN RELAPSED OR
REFRACTORY ACUTE MYELOID LEUKEMIA
    * RAFAEL HOLDINGS INC - AVENGER 500 PHASE 3 CLINICAL TRIAL
FOR
CPI-613® (DEVIMISTAT), LEAD PRODUCT CANDIDATE, DID NOT MEET ITS
PRIMARY ENDPOINT
    * RAFAEL HOLDINGS - INDEPENDENT DATA MONITORING COMMITTEE
RECOMMENDED PHASE 3 CLINICAL TRIAL IN RELAPSED OR REFRACTORY
ACUTE MYELOID LEUKEMIA BE STOPPED
    * RAFAEL HOLDINGS INC - WE PLAN TO WORK IN COLLABORATION
WITH
RAFAEL PHARMACEUTICALS TO FURTHER EVALUATE DATA

Source text for Eikon:  ID:nGNX7480Y9 
Further company coverage:  RFL.N 

 ((Reuters.Briefs@thomsonreuters.com;))